Subscribe to our Newsletters !!
Anemones Sea have a striking beauty and the abilit
Today, we live in a world of advanced biotechnolog
A new COVID-19 variant, BA.3.2, informally called
Alembic Pharmaceutica
Potassium cyanide is infamous in the world for the
Tofu used to be associated with Asian cuisine, but
Dear Readers, Welcome to a fresh and forward-look
Glenmark Pharmaceuticals on Tuesday said it has received approval from the US health regulator to market Clindamycin Phosphate Foam, an antibiotic used for treating bacterial infections, in the American market. The Mumbai-based firm has received final approval from the US Food and Drug Administration (USFDA) to market Clindamycin Phosphate Foam (1 per cent) which is a generic version of Mylan Pharmaceuticals Inc”s Evoclin Foam.
According to IQVIA sales data for the 12 month period ending July 2021, the Evoclin Foam, (1 per cent) had achieved annual sales of around USD 12 million.
Glenmark”s current portfolio consists of 173 products authorised for distribution in the US market place and 47 abbreviated new drug applications (ANDAs) are pending for approval with the USFDA.
In addition to these internal filings, the drug maker continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio, it stated.
Shares of the company were trading 1.03 per cent up at Rs 500.05 apiece on the BSE. PTI MSS DRR
DRR
